Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

ORIC anticipates the following upcoming data milestones: ORIC -114: 1H 2025: 2L EGFR exon 20 and 2L+ HER2 exon 20; 2H 2025: 2L+ EGFR atypical; 1H 2026: 1L EGFR exon 20; Mid-2026: 1L EGFR exon 20 ...

The ASX 200 pharmaceutical share notes that US FDA Fast Track designation is designed to facilitate the development and ...

The company raised $200 million after early findings hinted its therapy could be more potent than others like it, including ...

However, the shift of strategic direction to wellness has raised uncertainty over Kirin’s long-term growth prospects, where execution plays a key role in integrating the acquired subsidiary and ...

Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.

Solid Biosciences has surged back into the Duchenne muscular dystrophy (DMD) gene therapy race. | Solid Biosciences has ...